

---

## LIST OF FIGURES AND TABLES

---

### Chapter-1

Figure 1. 1: Illustrative anatomy of healthy human pancreas & its cytoarchitecture of exocrine and endocrine cells.....	4
Figure 1. 2: Endocrine lineage establishment & endocrine cells stratification, migration and cluster formation during mouse pancreas development.....	11
Figure 1. 3: Role of transcription factors in human pancreas development: Transcription factors (TF) regulatory network with a different stage of pancreatic islet development.....	14
Figure 1. 4: Pancreatic islets in a patient with type-I diabetes mellitus.....	20
Figure 1. 5: Different strategies for pancreas islet ( $\beta$ -cell) mass regeneration / replacement .	31
Figure 1. 6: MicroRNA biosynthesis and mode of action .....	34
Figure 1. 7: microRNA involved in pancreas development, $\beta$ -cell regeneration/ proliferation, and insulin secretion .....	35
Figure 1. 8: microRNAs expressed during <i>in vitro</i> differentiation of human embryonic stem cells into insulin producing cell clusters.....	37
Figure 1. 9: Role of swertisin,swertiamarin, and <i>Enicostemma littorale</i> (EL) in the treatment of type-I and type-II Diabetes .....	45
Table 1. 1: Positive and negative CD surface markers for identification of hBMSCs .....	33
Table 1. 2: MicroRNAs involved in the development of the human pancreas.....	36

### Chapter-3

Figure 3. 1 Structural feature of herbal medicinal plants (animal product: honey) and its bioactive molecules (active ingredients) that affect pancreatic islets function and diabetes...	60
Figure 3. 2: Representative flowchart of experimental design of chapter:3 .....	62
Figure 3. 3: Isolation and characterization of hBMSCs from Human BM subjects. (A) hBMSCs were isolated from adult human BM in KO-DMEM media. ....	71
Figure 3. 4: Characterization of isolated hBMSCs (Human BM) using flow cytometry .....	73
Figure 3. 5: Characterization of hBMSCs for stem cell and mesenchymal marker using both techniques confocal microscopy and flow cytometry.....	73

---

Figure 3. 6: Gene expression & protein expression of stemness markers in patient-derived hBMSCs.....	74
Figure 3. 7: Differentiation of hBMSCs to trilineage differentiation. ....	76
Figure 3. 8: Differentiation of hBMSCs into ILCCs (10 Day protocol).....	78
Figure 3. 9: Phase contrast microscopy of cell clusters at different stages (2 Day, 5 Day, 10 Day) of the islet differentiation process in serum-free media (SFM).....	79
Figure 3. 10: Differentiation of hBMSCs into ILCCs (18 <sup>th</sup> day protocol- non-adherent plates).....	80
Figure 3. 11: Curcumin reduced central necrosis during islet differentiation .....	81
Figure 3. 12: Schematic representation of phase contrast microscopic of differentiated ILCCs was getting merged during islet differentiation .....	83
Figure 3. 13: Differentiation of hBMSCs into ILCCs (18 <sup>th</sup> day protocol- Ultra-low adherent plates).....	84
Figure 3. 14: Analysis of total yield of ILCCs from hBMSCs using phase-contrast microscopic .....	85
Figure 3. 15: Morphometric analysis of hBMSCs generated 18 <sup>th</sup> Day ILCCs.....	86
Figure 3. 16: Live /Dead staining with FDA/PI dye at 18 <sup>th</sup> Day ILCCs by confocal microscopy .....	87
Figure 3. 17: Representative flow cytometry analysis of apoptosis using annexin V and propidium iodide (PI) staining .....	88
Figure 3. 18: Measurements of cellular (reactive oxygen species) ROS in 18 <sup>th</sup> day ILCCs by DCFDA assay. ....	89
Figure 3. 19: Heatmap displaying the relative gene expression of the top 11 upregulated genes at 18 <sup>th</sup> day ILCCs .....	90
Figure 3. 20: confocal immunocytochemistry of 18th Day ILCCs obtained at the end of the 18th islet differentiation protocol shows the expression of the functional pancreatic marker.	91
Figure 3. 21: confocal Immunocytochemistry of undifferentiated hBMSCs. ....	92
Figure 3. 22: Flow cytometry analysis of functional pancreatic islets marker in 18 <sup>th</sup> day ILCCs .....	93
Figure 3. 23: <i>In-vitro</i> functional characterization of differentiated 18 <sup>th</sup> day ILCCs by human c-peptide release assay (Chemiluminescence based ELISA, ALPCO, USA). ....	94
Figure 3. 24: Representative flow chart of summary of the chapter-3 .....	100

---

Table 3. 1: Characterization of human bone marrow volunteers and including & excluding criteria for human subject was enrolled in human bone marrow-derived mesenchymal stem cells isolation study.....	63
---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	----

#### Chapter 4

Figure 4. 1: Transcription factors involved in islet differentiation from mesoderm origin stem cell source i.e. hBMSCs.....	102
Figure 4. 2: Representative flow chart of experimental design of chapter-4 .....	104
Figure 4. 3: Flow chart of plan of work for chapter-4 .....	105
Figure 4. 4: qPCR detection temporal dynamics of gene expression of definitive endoderm marker from hBMSCs derived ILCCs .....	108
Figure 4. 5: qPCR detection temporal dynamics of gene expression of pancreatic progenitors' marker from hBMSCs derived ILCCs. ....	109
Figure 4. 6: qPCR detection temporal dynamics of gene expression of endocrine progenitors' marker from hBMSCs derived ILCCs .....	111
Figure 4. 7: qPCR detection temporal dynamics of gene expression of pancreatic islets specific marker from hBMSCs derived ILCCs .....	112
Figure 4. 8: Immunofluorescent images (confocal microscopy) of nestin protein expression in 5 <sup>th</sup> day cell clusters derived from hBMSCs using activin A and BMC .....	113
Figure 4. 9: Comparative confocal immunofluorescence expression of definite endoderm markers such as FOXA2 (Green), REG-1 (Red) and pancreatic progenitor as well as pancreatic endocrine markers such as PDX-1 (Green), NKX6.1(Green), NGN-3(Red), GLUT-2(Red) protein expression in 5 <sup>th</sup> Day cell clusters derived from hBMSCs using activin A and BMC. ....	115
Figure 4. 10: Comparative confocal immunofluorescence expression of definite endoderm markers such as FOXA2(Green) and pancreatic progenitor as well as pancreatic endocrine markers such as PDX-1 (Green), NGN-3(Red), NEUROD-1(Red) protein expression in 10 <sup>th</sup> day cell clusters (second stage) derived from hBMSCs using activin A and BMC .....	116
Figure 4. 11: Comparative confocal immunofluorescence expression of mature pancreatic progenitor markers such as NKX6.1(Green), NKX2.2 (Green) and mature pancreatic endocrine progenitor markers such as ARX (Red), PAX-4 (Red), NEUROD-1(Red) and terminal differentiated pancreatic islet hormones such as c-peptide and glucagon protein expression in 10 <sup>th</sup> day cell clusters (Second stage) derived from hBMSCs using activin A and BMC .....	117

---

Figure 4. 12: Comparative confocal immunofluorescence expression of definitive endoderm marker like FOXA2 (Green), REG-1(Red) and stem cell marker nestin (Red) along with mature pancreatic islet markers such as GLUT-2 (Green) protein expression in 15 <sup>th</sup> day cell clusters (Third stage) derived from hBMSCs using activin A and BMC .....	119
Figure 4. 13: Comparative confocal immunofluorescence expression of centrally important pancreatic progenitor markers like PDX-1(Green) and endocrine progenitor-like NGN-3(Red), NEUROD1(Green) protein expression in 15 <sup>th</sup> day cell clusters (Third stage) derived from hBMSCs using activin A and BMC.....	120
Figure 4. 14: Comparative confocal immunofluorescence expression of pancreatic and endocrine progenitor such as PDX-1(Green), NGN-3(Red) as well as terminal pancreatic differentiated markers such as NKX6.1 (Green), MAF-A(Red), GLUT-2 (Red), Glucagon (Green) protein expression in 18 <sup>th</sup> day ILCCs (Four stages) derived from hBMSCs using activin A and BMC .....	121
Figure 4. 15: Immunocytochemistry assay (confocal microscopy) of definitive endoderm transcription factors expression in single cells from ILCCs derived from hBMSCs using BMC .....	123
Figure 4. 16: Immunocytochemistry assay (confocal microscopy) of transcription factors expression in single cells from ILCCs derived from hBMSCs using BMC .....	124
Figure 4. 17: Immunocytochemistry assay (confocal microscopy) of transcription factors expression in single cells from ILCCs derived from hBMSCs using BMC .....	125
Figure 4. 18: immunocytochemistry assay of single cells from ILCCs: the single cells expressed mature pancreatic marker GLUT2 (Glucose transporter), also magnified images shows in lower penal (“White Arrow” for localization) .....	126
Figure 4. 19: Flow cytometry analysis of important pancreatic islets differentiation-related transcription factors on 10 <sup>th</sup> day cell clusters.....	127
Figure 4. 20: Protein profiling during islet differentiation from hBMSCs using western blot analysis.....	129
Figure 4. 21: Summary of chapter-4 .....	136

## Chapter 5

Figure 5. 1: microRNA 124a and its function related to pancreatic islets. miR-124a negative regulates the expression of various transcription factors and genes (related to insulin secretion) in pancreatic $\beta$ -cells. ....	138
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------	-----

---

Figure 5. 2 A schematic diagram show possible role of microRNAs in islet differentiation from hBMSCs.....	139
Figure 5. 3 : Representative image depicted that the molecular formation of locked nucleic acid (LNA), which represents the locked C3'-endo and C2'-endo sugar conformation.....	141
Figure 5. 4 Representative overviews of microRNA inhibition molecular mechanism of short LNAs.....	142
Figure 5. 5 Representative flow chart of experimental design .....	143
Figure 5. 6 Plan of work for microRNAs expression profile during islet differentiation from hBMSCs using activin A and bioactive molecules cocktail. ....	144
Figure 5. 7 Plan of work for inhibiting microRNAs -124a using power inhibitor LNA. ....	145
Figure 5. 8 The schematic diagram shows a step-wise protocol for isolating total RNA along with miRNA by utilizing miRNeasy MINI Kit (Qiagen, Germany). ....	146
Figure 5. 9 Schematic diagram on microRNAs cDNA synthesis and expression profile strategies based on Poly-A Tailing and SYBR green dye methods (qPCR). ....	147
Figure 5. 10 Heat map depicting the expression of 28 candidate miRNAs in Islet like cell clusters obtained at 10 <sup>th</sup> Day and 18 <sup>th</sup> Day of differentiation process from BMSCs from three different Non-diabetic patients. ....	150
Figure 5. 11: Candidate microRNA expression at 10 <sup>th</sup> & 18 <sup>th</sup> Day of islet like cell clusters of three different patients based on three patient's microRNA expression profile (previous heat map) .....	151
Figure 5. 12 Heat-map depicting the expression of 28 candidate miRNAs in Islet like cell clusters obtained at 5 <sup>th</sup> Day, 10 <sup>th</sup> Day,15 <sup>th</sup> Day and 18 <sup>th</sup> Day of differentiation process from BMSCs from one non-diabetic patient .....	153
Figure 5. 13: microRNA, gene expression, and protein expression during the islet differentiation stage: Day 5, Day 10, Day 15, and Day 18.....	154
Figure 5. 14 Immunofluorescent staining (using confocal microscopy) of FOXA-2 and NGN-3, definitive endoderm and pancreatic endocrine progenitor marker at 5 <sup>th</sup> Day of islet differentiation treated with and without power LNA-anti-miR124a (50nM concentration - Gymnosis method) in both BMC and activin A groups .....	156
Figure 5. 15 Immunofluorescent staining (using Confocal microscopy) of FOXA2 and NGN-3 protein expression .....	157
Figure 5. 16 Summary of Chapter 5.....	163

---

## Chapter 6

Figure 6. 1: Regenerative medicine is a multi-disciplinary field which comprises of various distinct disciplines.....	164
Figure 6. 2: Schematic representation of various stages involved in human islets transplantation.....	165
Figure 6. 3: Principle of Encapsulation.....	167
Figure 6. 4: An illustrative depiction of various micro & macro encapsulating materials and devices, which have been exploited for islets encapsulation and act as an immuno-isolation membrane.....	169
Figure 6. 5 Representative images regarding microstructure details of HFM (A) Psf-TPGS HFM. (B) SEM microstructure of HFM. (C) SEM micrographs of HFM showing asymmetric cross-section. (D) Inner membrane pores are in the nanometre range. (E) The outer membrane is a macro porous .....	170
Figure 6. 6: Representative graphical analysis of HFM properties. ....	171
Figure 6. 7: plan of work for Chapter-6 ( <i>In vitro</i> ) .....	173
Figure 6. 8: plans of work for Chapter-6 ( <i>In vivo</i> ). ....	173
Figure 6. 9: Encapsulated rat islet viability study ( <i>In vitro</i> ). ....	174
Figure 6. 10: Experimental time-line for xeno-transplantation study ( <i>In-vivo</i> ). ....	174
Figure 6. 11: Experimental process (steps) for xeno- transplantation study ( <i>In vivo</i> ). ....	175
Figure 6. 12: Encapsulated ILCCs (hBMSCs differentiated into ILCCs using 18-day protocol) were observed by phase-contrast microscopy.....	179
Figure 6. 13: Fluorescence microscopies of Annexin V-FITC (green) & propidium iodide (red) staining of retrieved encapsulated ILCCs (differentiated from hBMSCs) from HFM, after 48-hrs. incubation in RPMI media containing non-diabetic mouse serum & diabetic mouse serum .....	180
Figure 6. 14: Freshly isolated and overnight culture rat pancreatic islets. ....	182
Figure 6. 15: Fluorescence microscopies of FITC-Annexin V (green) & propidium iodide (red) staining of retrieved encapsulated adult rat islets from HFM, after 48-hour incubation in RPMI media containing non-diabetic mouse serum & diabetic mouse serum.....	183
Figure 6. 16: Graph of change body weight (in gram) of pre-and post-transplantation duration in non- diabetic control (blue), Diabetic control (red), diabetic mice transplanted with encapsulated rat islets-HFM (green).....	184

Figure 6. 17: Reversal of experimental diabetes in the STZ-treated Balb/C mice model. Fasting Blood Sugar (FBS) levels (in mg/dl) in non- diabetic control mice (blue), Diabetic control mice (red) and diabetic mice transplanted with encapsulated rat islets into HFM (green) in intraperitoneal cavity area.....	185
Figure 6. 18: Retrieval of HFM from transplanted diabetic mice model.....	186
Figure 6. 19: Summary of Chapter-6 ( <i>in vitro</i> and <i>in vivo</i> study).....	193
Table 6. 1: Advantages & limitations of macro & microencapsulation devices (Desai <i>et al.</i> 2006) .....	168
Table 6. 2: Various islets/ $\beta$ cell encapsulation systems undergoing clinical trials (Desai and Shea 2017). .....	169